Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $97.33 Average PT from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been given an average recommendation of “Moderate Buy” by the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $97.3333.

A number of equities analysts have weighed in on the stock. Morgan Stanley raised their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, July 23rd. Piper Sandler restated an “overweight” rating and issued a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Weiss Ratings lowered Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. Sanford C. Bernstein lifted their price objective on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Finally, Leerink Partners boosted their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a report on Wednesday, June 17th.

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $85.59 on Friday. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The firm has a market capitalization of $12.06 billion, a P/E ratio of -38.04 and a beta of 1.27. The business has a fifty day simple moving average of $81.10 and a two-hundred day simple moving average of $72.05. Arrowhead Pharmaceuticals has a 12 month low of $18.14 and a 12 month high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to analysts’ expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The firm’s quarterly revenue was up 171.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.26) earnings per share. On average, equities analysts forecast that Arrowhead Pharmaceuticals will post -3.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ARWR. Versant Capital Management Inc increased its stake in Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 248 shares in the last quarter. Carolina Wealth Advisors LLC raised its holdings in Arrowhead Pharmaceuticals by 80.6% in the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after buying an additional 154 shares during the last quarter. Tsfg LLC bought a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter worth approximately $25,000. Optiver Holding B.V. lifted its stake in shares of Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after buying an additional 186 shares in the last quarter. Finally, First Horizon Corp purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $32,000. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.